Equities

United Therapeutics Corp

United Therapeutics Corp

Actions
  • Price (EUR)376.20
  • Today's Change-4.60 / -1.21%
  • Shares traded10.00
  • 1 Year change+80.00%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 16:12 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments2,9942,8391,931
Total Receivables, Net279220199
Total Inventory11210294
Prepaid expenses------
Other current assets, total166219100
Total current assets3,5513,3802,324
Property, plant & equipment, net1,045862781
Goodwill, net342828
Intangibles, net811717
Long term investments1,9381,3161,650
Note receivable - long term------
Other long term assets123114108
Total assets7,1676,0455,169
LIABILITIES
Accounts payable5.604.103.80
Accrued expenses292226171
Notes payable/short-term debt000
Current portion long-term debt/capital leases400----
Other current liabilities, total106113131
Total current liabilities804343305
Total long term debt300800800
Total debt700800800
Deferred income tax------
Minority interest------
Other liabilities, total78105105
Total liabilities1,1821,2481,210
SHAREHOLDERS EQUITY
Common stock0.700.700.70
Additional paid-in capital2,5492,3882,245
Retained earnings (accumulated deficit)6,0275,0424,315
Treasury stock - common(2579)(2579)(2579)
Unrealized gain (loss)(11)(56)(4.6)
Other equity, total(2)0.90(18)
Total equity5,9854,7973,959
Total liabilities & shareholders' equity7,1676,0455,169
Total common shares outstanding474645
Treasury shares - common primary issue272727
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.